Compare
Cogent Biosciences, Inc. vs BridgeBio Pharma, Inc. vs Viridian Therapeutics, Inc. vs Xencor Inc
| Latest fiscal year | Cogent Biosciences, Inc. COGT | BridgeBio Pharma, Inc. BBIO | Viridian Therapeutics, Inc. VRDN | Xencor Inc XNCR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $502.08M | $70.85M | $125.58M |
| Revenue growth (YoY) | n/a | +126.3% | n/m | +13.7% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -104.2% | -512.9% | -141.4% |
| Net margin | n/a | -146.0% | -483.6% | -73.2% |
| Net income | -$328.94M | -$732.94M | -$342.60M | -$91.92M |
| EPS (Diluted) | -$2.16 | -$3.78 | n/a | -$1.24 |
| Operating cash flow | -$264.44M | -$445.91M | -$276.39M | -$135.12M |
| Free cash flow | -$266.00M | -$447.01M | -$276.89M | -$138.27M |
| Cash & equivalents | $312.01M | $570.12M | n/a | $54.07M |
| Total assets | $937.61M | $936.02M | $899.42M | $875.50M |
| Total liabilities | $301.24M | $3.01B | $177.25M | $239.91M |
| Shareholders' equity | $636.37M | -$2.09B | $722.17M | $635.59M |
| Return on year-end equity | -51.7% | n/a | -47.4% | -14.5% |
| Shares outstanding | 160.98M | 194.77M | 101.83M | 71.87M |
Revenue, most recent five fiscal years
| Fiscal year | Cogent Biosciences, Inc. | BridgeBio Pharma, Inc. | Viridian Therapeutics, Inc. | Xencor Inc |
|---|---|---|---|---|
| Latest | $7.87M Ended 2020-12-31 | $502.08M Ended 2025-12-31 | $70.85M Ended 2025-12-31 | $125.58M Ended 2025-12-31 |
| 1 year earlier | $22.50M Ended 2019-12-31 | $221.90M Ended 2024-12-31 | $302.0K Ended 2024-12-31 | $110.49M Ended 2024-12-31 |
| 2 years earlier | $9.73M Ended 2018-12-31 | $9.30M Ended 2023-12-31 | $314.0K Ended 2023-12-31 | $174.62M Ended 2023-12-31 |
| 3 years earlier | $8.36M Ended 2017-12-31 | $77.65M Ended 2022-12-31 | $1.77M Ended 2022-12-31 | $164.58M Ended 2022-12-31 |
| 4 years earlier | n/a | $69.72M Ended 2021-12-31 | $2.96M Ended 2021-12-31 | $275.11M Ended 2021-12-31 |